Manhattan Behavioral Medicine

New York, New York 10036-4543

4 studies enrolling now · 29 studies all time

What they study most

Adjunctive Treatment of Major Depressive Disorder, Agitation Associated With Alzheimer's Disease Dementia, Alzheimer Disease, Alzheimer's Disease, Anhedonia, Attention Deficit Hyperactivity Disorder (ADHD), Binge-Eating Disorder, Bipolar Disorder, Bipolar I Disorder, Depression, Depressive Disorder, Major, Generalized Anxiety Disorder

Studies at this site

• A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder — Recruiting now
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — Recruiting now
• Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. — Recruiting now
• Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia — Recruiting now
• Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder — Completed
• A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) — Stopped early
• A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy — Completed
• A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder — Completed
• A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder — Completed
• A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder — Completed
• A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine — Completed
• SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study — Completed
• Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Participants Aged 7 to 11 Years With Major Depressive Disorder (MDD) — Completed
• Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Intermittent Explosive Disorder — Stopped early
• Safety and Efficacy Study of ALZT-OP1 in Subjects With Evidence of Early Alzheimer's Disease — Completed
• Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease — Completed
• Efficacy and Safety Trial of Flexible Doses of Oral Ziprasidone in Children and Adolescents With Bipolar I Disorder — Stopped early
• Safety and Efficacy Study in Preschool Children Aged 4-5 Years With Attention-deficit/Hyperactivity Disorder (ADHD) — Completed
• Trial to Evaluate the Long-term Efficacy of Oral Aripiprazole in the Treatment of Pediatric Participants With Tourette's Disorder — Stopped early
• Safety and Tolerability Study of SPD489 in Preschool Children Aged 4-5 Years, Diagnosed With Attention-deficit/Hyperactivity Disorder — Completed
• Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder — Completed
• Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD) — Stopped early
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder — Completed
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder — Completed
• Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY) — Completed
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03) — Completed
• Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22) — Completed
• A Study of Vilazodone in Pediatric Patients With Major Depressive Disorder — Completed
• Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder — Completed